Overview Financials News + Filings Key Docs Charts Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Director departure
Inv. presentation
Appointed director
|
|
MARIZYME, INC. (MRZM)
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 12/27/2021 |
8-K
| Entered into consulting agreement, Appointed a new director|
Docs:
|
"Appointment of Agent and Unitholder Representative",
"Plan of Distribution",
"WIRE INSTRUCTIONS FORM OF CONVERSION NOTICE The undersigned hereby irrevocably elects to convert $ ________________ of the principal amount of the above Note No. ___ into shares of Common Stock of Marizyme, Inc. according to the conditions hereof, as of the date written below. Date of Conversion: Conversion Price: Number of shares of Common Stock beneficially owned or deemed beneficially owned by the Holder on the Conversion Date:",
"MARIZYME, INC. Class C COMMON STOCK PURCHASE WARRANT Marizyme, Inc., a Nevada corporation , hereby certifies that, for value received, [_________], a [_________] , is entitled, subject to the terms set forth below, to purchase from the Company at any time during the Exercise Period up to [_____________] fully paid and non-assessable shares of Common Stock , at a purchase price per share equal to the Exercise Price . The number of shares of Common Stock for which this Class C Common Stock Purchase Warrant is exercisable and the Exercise Price are subject to adjustment as provided herein. 1. DEFINITIONS . Certain terms are used in this Warrant as specifically defined in Section 9 . 2. EXERCISE OF WARRANT . 2.1. Exercise . This Warrant may be exercised prior to its expiration pursuant to Sect...",
"EXCHANGE AGREEMENT",
"Placement Agency Agreement between Marizyme, Inc. and Univest Securities, LLC",
"Warrant Agreement",
"MARIZYME ANNOUNCES THE CLOSING OF MY HEALTH LOGIC ACQUISITION ALONG WITH INITIAL FINANCING JUPITER, Fla., December 23, 2021 /PRNewswire/ — Marizyme Inc. , is pleased to announce the closing of its acquisition of My Health Logic Inc., a subsidiary of Health Logic Interactive Inc. , along with a concurrent financing. My Health Logic’ s “lab-on-chip” technology platform and patient-centric digital point-of-care device, MATLOC 1, further strengthens Marizyme’ s life science technology product pipeline. Marizyme is actively seeking FDA approval for both MATLOC1 and a second product, DuraGraft. My Health Logic’ s MATLOC and Lab-on-Chip Technology Platform The excitement over microfluidics, also known as lab-on-a-chip technology, lies in its potential for producing revolutionary, timely, accessib..." |
|
| 09/21/2009 |
8-K
| Form 8-K - Current report |
|
|